The roles of epithelial-to-mesenchymal transition (EMT) and mesenchymal-to-epithelial transition (MET) in breast cancer bone metastasis: Potential targets for prevention and treatment

Journal of Clinical Medicine

Volumn 2, Issue 4, 2013, Pages 264-282

  Demirkan, Binnaz ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Breast cancer bone metastasis; Epithelial to mesenchymal transition (EMT); Mesenchymal to epithelial transition (MET); Prevention; Treatment

Indexed keywords

BONE MORPHOGENETIC PROTEIN; CATHEPSIN K; CD24 ANTIGEN; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HERMES ANTIGEN; HISTONE DEACETYLASE INHIBITOR; MATRIX METALLOPROTEINASE; METHYLENETETRAHYDROFOLATE DEHYDROGENASE; MICRORNA; NOTCH RECEPTOR; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOGENIC PROTEIN 1; OSTEONECTIN; PERIFOSINE; PROTEIN LYSINE 6 OXIDASE; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE 2; SOMATOMEDIN B; SOMATOMEDIN C; SUNITINIB; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR TWIST; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR; UNINDEXED DRUG; UVOMORULIN; VASCULOTROPIN; VIMENTIN; VITRONECTIN RECEPTOR; WNT PROTEIN;

APOPTOSIS; BONE MARROW TUMOR; BONE METASTASIS; BREAST CARCINOGENESIS; BREAST CARCINOMA; BREAST EPITHELIUM; BREAST METASTASIS; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER STAGING; CANCER STEM CELL; DNA METHYLATION; EPITHELIAL MESENCHYMAL TRANSITION; EXOSOME; HUMAN; MESENCHYMAL EPITHELIAL TRANSITION; MESENCHYMAL STEM CELL; OSTEOLYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; REVIEW; RNA INTERFERENCE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR BLOOD FLOW; TUMOR INVASION;

EID: 84978878644     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm2040264     Document Type: Review

References (143)

1. Buijs, J.T.; van der Pluijm, G. Osteotropic cancers: From primary tumor to bone. Cancer Lett. 2009, 273, 177-193.
2. Sporn, M.B. The war on cancer. Lancet 1996, 347, 1377-1381.
3. Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin. 2011, 61, 69-90.
4. Sainsbury, R. The development of endocrine therapy for women with breast cancer. Cancer Treat. Rev. 2013, 39, 507-517.
5. Rao, R.D.; Cobleigh, M.A. Adjuvant endocrine therapy for breast cancer. Oncology (Williston Park) 2012, 26, 541-547.
6. Hernandez-Aya, L.F.; Gonzalez-Angulo, A.M. Adjuvant systemic therapies in breast cancer. Surg. Clin. North Am. 2013, 93, 473-491.
7. Vrbic, S.; Pejcic, I.; Filipovic, S.; Kocic, B.; Vrbic, M. Current and future anti-HER2 therapy in breast cancer. J. BUON 2013, 18, 4-16.
8. Joerger, M.; Thürlimann, B. Chemotherapy regimens in early breast cancer: Major controversies and future outlook. Expert Rev. Anticancer Ther. 2013, 13, 165-178.
9. Andre, F.; Dieci, M.V.; Dubsky, P.; Sotiriou, C.; Curigliano, G.; Denkert, C.; Loi, S. Molecular pathways: Involvement of immune pathways in the therapeutic response and outcome in breast cancer. Clin. Cancer Res. 2013, 19, 28-33.
10. Coleman, R.E. Skeletal complications of malignancy. Cancer 1997, 80, 1588-1594.
11. Steinman, R.A.; Brufsky, A.M.; Oesterreich, S. Zoledronic acid effectiveness against breast cancer metastases-A role for estrogen in the microenvironment? Breast Cancer Res. 2012, 14, doi:10.1186/bcr3223.
12. Lipton, A. Future treatment of bone metastases. Clin. Cancer Res. 2006, 12, 6305-6308.
13. Bouganim, N.; Dranitsaris, G.; Amir, E.; Clemons, M. Optimizing the use of bone-targeted agents in patients with metastatic cancers: A practical guide for medical oncologists. Support. Care Cancer 2011, 19, 1687-1696.
14. Rose, A.A.; Siegel, P.M. Emerging therapeutic targets in breast cancer bone metastases. Future Oncol. 2010, 6, 55-74.
15. Lee, B.L.; Higgins, M.J.; Goss, P.E. Denosumab and the current status of bone-modifying drugs in breast cancer. Acta Oncol. 2012, 51, 157-167.
16. Stopeck, A.T.; Lipton, A.; Body, J.J.; Steger, G.G.; Tonkin, K.; de Boer, R.H.; Lichinitser, M.; Fujiwara, Y.; Yardley, D.A.; Viniegra, M.; et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J. Clin. Oncol. 2010, 28, 5132-5139.
17. Young, R.J.; Coleman, R.E. Zoledronic acid to prevent and treat cancer metastasis: New prospects for an old drug. Future Oncol. 2013, 9, 633-643.
18. Casas, A.; Llombart, A.; Martín, M. Denosumab for the treatment of bone metastases in advanced breast cancer. Breast 2013, 22, 585-592.
19. Chang, J.C.; Wooten, E.C.; Tsimelzon, A.; Hilsenbeck, S.G.; Gutierrez, M.C.; Tham, Y.L.; Kalidas, M.; Elledge, R.; Mohsin, S.; Osborne, C.K.; et al. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J. Clin. Oncol. 2005, 23, 169-177.
20. Li, X.; Lewis, M.T.; Huang, J.; Gutierrez, C.; Osborne, C.K.; Wu, M.F.; Hilsenbeck, S.G.; Pavlick, A.; Zhang, X.; Chamness, G.C.; et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl. Cancer Inst. 2008, 100, 672-679.
21. Creighton, C.J.; Li, X.; Landis, M.; Dixon, J.M.; Neumeister, V.M.; Sjolund, A.; Rimm, D.L.; Wong, H.; Rodriguez, A.; Herschkowitz, J.I.; et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc. Natl. Acad. Sci. USA 2009, 106, 13820-13825.
22. Li, Q.Q.; Xu, J.D.; Wang, W.J.; Cao, X.X.; Chen, Q.; Tang, F.; Chen, Z.Q.; Liu, X.P.; Xu, Z.D. Twist1-mediated adriamycin-induced epithelial mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin. Cancer. Res. 2009, 15, 2657-2665.
23. Van der Pluijm, G. Epithelial plasticity, cancer stem cells and bone metastasis formation. Bone 2011, 48, 37-43.
24. Dave, B.; Mittal, V.; Tan, N.M.; Chang, J.C. Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Res. 2012, 14, 202.
25. Thiery, J.P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002, 2, 442-454.
26. Chambers, A.F.; Groom, A.C.; MacDonald, I.C. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2002, 2, 563-572.
27. Cardiff, R.D.; Couto, S.; Bolon, B. Three interrelated themes in current breast cancer research: Gene addiction, phenotypic plasticity, and cancer stem cells. Breast Cancer Res. 2011, 13, doi:10.1186/bcr2887.
28. Takebe, N.; Warren, R.Q.; Ivy, S.P. Breast cancer growth and metastasis: İnterplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition. Breast Cancer Res. 2011, 13, doi:10.1186/bcr2876.
29. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell 2000, 100, 57-70.
30. Weidner, N.; Folkman, J.; Pozza, F.; Bevilacqua, P.; Allred, E.N.; Moore, D.H.; Meli, S.; Gasparini, G. Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma. J. Natl. Cancer Inst. 1992, 84, 1875-1887.
31. Folkman, J.; Shing, Y. Angiogenesis. J. Biol. Chem. 1992, 267, 10931-10934.
32. Folkman, J. The role of angiogenesis in tumor growth. Semin. Cancer Biol. 1992, 3, 65-71.
33. Kiaris, H.; Chatzistamou, I.; Kalofoutis, C.; Koutselini, H.; Piperi, C.; Kalofoutis, A. Tumour-stroma interactions in carcinogenesis: Basic aspects and perspectives. Mol. Cell. Biochem. 2004, 261, 117-122.
34. Pupa, S.M.; Menard, S.; Forti, S.; Tagliabue, E. New insights into the role of extracellular matrix during tumor onset and progression. J. Cell. Physiol. 2002, 192, 259-267.
35. Wells, A.; Chao, Y.L.; Grahovac, J.; Wu, Q.; Lauffenburger, D.A. Epithelial and mesenchymal phenotypic switchings modulate cell motility in metastasis. Front. Biosci. 2011, 16, 815-837.
36. Mathias, R.A.; Gopala, S.K.; Simpson, R.J. Contribution of cells undergoing epithelial-mesenchymal transition to the tumour microenvironment. J. Proteomics 2013, 78, 545-557.
37. Gunasinghe, N.P.A.D.; Wells, A.; Thompson, E.W.; Hugo, H.J. Mesenchymal-epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancer. Cancer Metastasis Rev. 2012, 31, 469-478.
38. Zeisberg, M.; Neilson, E.G. Biomarkers for epithelial-mesenchymal transitions. J. Clin. Invest. 2009, 119, 1429-1437.
39. Al-Hajj, M.; Wicha, M.S.; Benito-Hernandez, A.; Morrison, S.J.; Clarke, M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100, 3983-3988.
40. Blick, T.; Hugo, H.; Widodo, E.; Waltham, M.; Pinto, C.; Mani, S.A.; Weinberg, R.A.; Neve, R.M.; Lenburg, M.E.; Thompson, E.W. Epithelial mesenchymal transition traits in human breast cancer cell lines paralel the CD44 (hi)/CD24 (lo/-) stem cell phenotype in human breast cancer. J. Mammary Gland Biol. Neoplasia 2010, 15, 235-252.
41. Beug, H. Breast cancer stem cells: Eradication by differentiation therapy? Cell 2009, 138, 623-625.
42. Woelfle, U.; Cloos, J.; Sauter, G.; Riethdorf, L.; Janicke, F.; van Diest, P.; Brakenhoff, R.; Pantel, K. Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res. 2003, 63, 5679-5684.
43. Wang, Y.; Zhou, B.P. Epithelial-mesenchymal transition in breast cancer progression and metastasis. Chin. J. Cancer 2011, 30, 603-611.
44. Morel, A.P.; Lievre, M.; Thomas, C.; Hinkal, G.; Ansieau, S.; Puisieux, A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 2008, 3, e2888.
45. Paget, S. The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev. 1989, 8, 98-101.
46. Pratap, J.; Lianb, J.B.; Steinb, G.S. Metastatic bone disease: Role of transcription factors and future targets. Bone 2011, 48, 30-36.
47. Vallone, V.B.F.; Hofer, E.L.; Choi, H.; Bordenave, R.H.; Batagelj, E.; Feldman, L.; La Russa, V.; Caramutti, D.; Dimase, F.; Labovsky, V.; et al. Behaviour of mesenchymal stem cells from bone marrow of untreated advanced breast and lung cancer patients without bone osteolytic metastasis. Clin. Exp. Metastasis 2013, 30, 317-332.
48. Josson, S.; Nomura, T.; Lin, J.-T.; Huang, W.-C.; Wu, D.; Zhau, H.E.; Zayzafoon, M.; Weizmann, M.N.; Gururajan, M.; Chung, L.W.K. Transition and confers cancer lethality and bone β2-microglobulin induces epithelial to mesenchymal metastasis in human cancer cells. Cancer Res. 2011, 71, 2600-2610.
49. Martin, F.T.; Dwyer, R.M.; Kelly, J.; Khan, S.; Murphy, J.M.; Curran, C.; Miller, N.; Hennessy, E.; Dockery, P.; Barry, F.P.; et al. Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: Stimulation of epithelial to mesenchymal transition (EMT). Breast Cancer Res. Treat. 2010, 124, 317-326.
50. Jain, V.K.; Turner, N.C. Challenges and opportunities in the targeting of fibroblast growth factor receptors in breast cancer. Breast Cancer Res. 2012, 14, 208.
51. Martorana, A.M.; Zheng, G.; Crowe, T.C.; O'Grady, R.L.; Lyons, J.G. Epithelial cells up-regulate matrix metalloproteinases in cells within the same mammary carcinoma that have undergone an epithelial-mesenchymal transition. Cancer Res. 1998, 58, 4970-4979.
52. Scheel, C.; Eaton, E.N.; Li, S.H.; Chaffer, C.L.; Reinhardt, F.; Kah, K.J.; Bell, G.; Guo, W.; Rubin, J.; Richardson, A.L.; et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 2011, 145, 926-940.
53. Boyle, W.J.; Simonet, W.S.; Lacey, D.L. Osteoclast differentiation and activation. Nature 2003, 423, 337-342.
54. Guise, T.A.; Chirgwin, J.M. Transforming growth factor-β in osteolytic breast cancer bone metastases. Clin. Orthop. 2003, 415, 32-38.
55. Buijs, T.J.; Stayrook, K.R.; Guise, T.A. TGF-β in the bone microenvironment: Role in breast cancer metastases. Cancer Microenviron. 2011, 4, 261-281.
56. Deckers, M.; van Dinther, M.; Buijs, J.; Que, I.; Lowik, C.; van der Pluijm, G.; ten Dijke, P. The tumor suppressor Smad4 is required for transforming growth factor B-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res. 2006, 66, 2202-2209.
57. Giehl, K.; Imamichib, Y.; Menke, A. Smad4-independent TGF-β signaling in tumor cell migration. Cells Tissues Organs 2007, 185, 123-130.
58. Sundqvist, A.; ten Dijke, P.; van Dam, H. Key signaling nodes in mammary gland development and cancer: Smad signal integration in epithelial cell plasticity. Breast Cancer Res. 2012, 14, doi:10.1186/bcr3066.
59. Gal, A.; Sjoblom, T.; Fedorova, L.; Imreh, S.; Beug, H.; Moustakas, A. Sustained TGF beta exposure suppresses Smad and non-Smad signalling in mammary epithelial cells, leading to EMT and inhibition of growth arrest and apoptosis. Oncogene 2008, 27, 1218-1230.
60. Roberts, A.B.; Wakefield, L.M. The two faces of transforming growth factor β in carcinogenesis. Proc. Natl. Acad. Sci. USA 2003, 100, 8621-8623.
61. Ten Dijke, P.; Goumans, M.-J.; Itoh, F.; Itoh, S. Regulation of cell proliferation by Smad proteins. J. Cell. Physiol. 2002, 191, 1-16.
62. Yin, J.J.; Selander, K.; Chirgwin, J.M.; Dallas, M.; Grubbs, B.G.; Wieser, R.; Massagué, J.; Mundy, G.R.; Guise, T.A. TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 1999, 103, 197-206.
63. Tanos, T.; Rojo, L.J.; Echeverria, P.; Brisken, C. ER and PR signaling nodes during mammary gland development. Breast Cancer Res. 2012, 14, doi:10.1186/bcr3166.
64. Beleut, M.; Rajaram, R.D.; Caikovski, M.; Ayyanan, A.; Germano, D.; Choi, Y.; Schneider, P.; Brisken, C. Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc. Natl. Acad. Sci. USA 2009, 107, 2989-2994.
65. Joshi, P.A.; Jackson, H.W.; Beristain, A.G.; di Grappa, M.A.; Mote, P.A.; Clarke, C.L.; Stingl, J.; Waterhouse, P.D.; Khokha, R. Progesterone induces adult mammary stem cell expansion. Nature 2010, 465, 803-807.
66. Asselin-Labat, M.L.; Vaillant, F.; Sheridan, J.M.; Pal, B.; Wu, D.; Simpson, E.R.; Yasuda, H.; Smyth, G.K.; Martin, T.J.; Lindeman, G.J.; et al. Control of mammary stem cell function by steroid hormone signalling. Nature 2010, 465, 798-802.
67. Hinck, L.; Silberstein, G.B. Key stages in mammary gland development: The mammary end bud as a motile organ. Breast Cancer Res. 2005, 7, 245-251.
68. Tanos, T.; Sflomos, G.; Echeverria, P.C.; Ayyanan, A.; Gutierrez, M.; Delaloye, J.F.; Raffoul, W.; Fiche, M.; Dougall, W.; Schneider, P.; et al. Progesterone/RANKL is a major regulatory axis in the human breast. Sci. Transl. Med. 2013, 5, doi:10.1126/scitranslmed.3005654.
69. Ismail, P.M.; DeMayo, F.J.; Amato, P.; Lydon, J.P. Progesterone induction of calcitonin expression in the murine mammary gland. J. Endocrinol. 2004, 180, 287-295.
70. Andrews, J.L.; Kim, A.C.; Hens, J.R. The role and function of cadherins in the mammary gland. Breast Cancer Res. 2012, 14, doi:10.1186/bcr3065.
71. Kowalski, P.J.; Rubin, M.A.; Kleer, C.G. E-Cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res. 2003, 5, 217-222.
72. Berx, G.; Staes, K.; van Hengel, J.; Molemans, F.; Bussemakers, M.J.; van Bokhoven, A.; van Roy, F. Cloning and characterization of the human invasion suppressor gene E cadherin (CDH1). Genomics 1995, 26, 281-289.
73. Pecina-Slaus, N. Tumor suppressor gene E-cadherin and its role in normal and malignant cells. Cancer Cell Int. 2003, 3, doi:10.1186/1475-2867-3-17.
74. Perl, A.K.; Wilgenbus, P.; Dahl, U.; Semb, H.; Christofori, G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 1998, 392, 190-193.
75. Wells, A.; Yates, C.; Shepard, C.R. E-Cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas. Clin. Exp. Metastasis 2008, 25, 621-628.
76. Saha, B.; Chaiwun, B.; Imam, S.S.; Tsao-Wei, D.D.; Groshen, S.; Naritoku, W.Y.; Imam, S.A. Overexpression of E-cadherin protein in metastatic breast cancer cells in bone. Anticancer Res. 2007, 27, 3903-3908.
77. Lehtinen, L.; Ketola, K.; Mäkelä, R.; Mpindi, J.P.; Viitala, M.; Kallioniemi, O.; Iljin, K. High-throughput RNAi screening for novel modulators of vimentin expression identifies MTHFD2 as a regulator of breast cancer cell migration and invasion. Oncotarget 2013, 4, 48-63.
78. Gregory, P.A.; Bert, A.G.; Paterson, E.L.; Barry, S.C.; Tsykin, A.; Farshid, G.; Vadas, M.A.; Khew-Goodall, Y.; Goodall, G.J. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 2008, 10, 593-601.
79. Brabletz, S.; Brabletz, T. The ZEB/miR-200 feedback loop-A motor of cellular plasticity in development and cancer? EMBO Rep. 2010, 11, 670-677.
80. Gregory, P.A.; Bracken, C.P.; Smith, E.; Bert, A.G.; Wright, J.A.; Roslan, S.; Morris, M.; Wyatt, L.; Farshid, G.; Lim, Y.Y.; et al. An autocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol. Biol. Cell 2011, 22, 1686-1698.
81. Burk, U.; Schubert, J.; Wellner, U.; Schmalhofer, O.; Vincan, E.; Spaderna, S.; Brabletz, T. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008, 9, 582-589.
82. Brabletz, S.; Bajdak, K.; Meidhof, S.; Burk, U.; Niedermann, G.; Firat, E.; Wellner, U.; Dimmler, A.; Faller, G.; Schubert, J.; et al. The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. EMBO J. 2011, 30, 770-782.
83. Bullock, M.D.; Sayan, A.E.; Packham, G.K.; Mirnezami, A.H. MicroRNAs: Critical regulators of epithelial to mesenchymal (EMT) and mesenchymal to epithelial transition (MET) in cancer progression. Biol. Cell 2012, 104, 3-12.
84. Schwarzenbacher, D.; Balic, M.; Pichler, M. The role of microRNAs in breast cancer stem cells. Int. J. Mol. Sci. 2013, 14, 14712-14723.
85. Hwang, M.S.; Yu, N.; Stinson, S.Y.; Yue, P.; Newman, R.J.; Allan, B.B.; Dornan, D. miR-221/222 targets adiponectin receptor 1 to promote the epithelial-to-mesenchymal transition in breast cancer. PLoS One 2013, 8, e66502.
86. Shimono, Y.; Zabala, M.; Cho, R.W.; Lobo, N.; Dalerba, P.; Qian, D.; Diehn, M.; Liu, H.; Panula, S.P.; Chiao, E.; et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009, 138, 592-603.
87. Ma, L.; Teruya-Feldstein, J.; Weinberg, R.A. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007, 449, 682-688.
88. De Herreros, A.G.; Peiro, S.; Nassour, M.; Savagner, P. Snail family regulation and epithelial mesenchymal transitions in breast cancer progression. J. Mammary Gland Biol. Neoplasia 2010, 15, 135-147.
89. Maeda, M.; Johnson, K.R.; Wheelock, M.J. Cadherin switching: Essential for behavioral but not morphological changes during an epithelium-to-mesenchyme transition. J. Cell Sci. 2005, 118, 873-887.
90. Cano, A.; Perez-Moreno, M.A.; Rodrigo, I.; Locascio, A.; Blanco, M.J.; del Barrio, M.G.; Portillo, F.; Nieto, M.A. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat. Cell Biol. 2000, 2, 76-83.
91. El-Haibia, C.P.; Bellb, G.W.; Zhangc, J.; Collmanna, A.Y.; Woodd, D.; Scherbere, C.M.; Csizmadiaf, E.; Marianig, O.; Zhua, C.; Campagne, A.; et al. Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy. PNAS 2012, 109, 17460-17465.
92. Korpal, M.; Ell, B.J.; Buffa, F.M.; Ibrahim, T.; Blanco, M.A.; Celià-Terrassa, T.; Mercatali, L.; Khan, Z.; Goodarzi, H.; Hua, Y.; et al. Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat. Med. 2011, 17, 1101-1108.
93. Mathivanan, S.; Ji, H.; Simpson, R.J. Exosomes: Extracellular organelles important in intercellular communication. J. Proteomics 2010, 73, 1907-1920.
94. Janowska-Wieczorek, A.; Marquez-Curtis, L.A.; Wysoczynski, M.; Ratajczak, M.Z. Enhancing effect of platelet-derived microvesicles on the invasive potential of breast cancer cells. Transfusion 2006, 46, 1199-1209.
95. Friel, A.M.; Corcoran, C.; Crown, J.; O'Driscoll, L. Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer. Breast Cancer Res. Treat. 2010, 123, 613-625.
96. Simpson, R.J.; Jensen, S.S.; Lim, J.W. Proteomic profiling of exosomes: Current perspectives. Proteomics 2008, 8, 4083-4099.
97. Thery, C.; Zitvogel, L.; Amigorena, S. Exosomes: Composition, biogenesis and function. Nat. Rev. Immunol. 2002, 2, 569-579.
98. Katsuno, Y.; Lamouille, S.; Derynck, R. TGF-β signaling and epithelial-mesenchymal transition in cancer progression. Curr. Opin. Oncol. 2013, 25, 76-84.
99. Rappa, G.; Mercapide, J.; Lorico, A. Spontaneous formation of tumorigenic hybrids between breast cancer and multipotent stromal cells is a source of tumor heterogeneity. Am. J. Pathol. 2012, 180, 2504-2515.
100. Sabbah, M.; Emami, S.; Redeuilh, G.; Julien, S.; Prévost, G.; Zimber, A.; Ouelaa, R.; Bracke, M.; de Wever, O.; Gespach, C. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resist. Updat. 2008, 11, 123-151.
101. Shore, P.A. Role for Runx2 in normal mammary gland and breast cancer bone metastasis. J. Cell. Biochem. 2005, 96, 484-489.
102. Pratap, J.; Lian, J.B.; Javed, A.; Barnes, G.L.; van Wijnen, A.J.; Stein, J.L.; Stein, G.S. Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev. 2006, 25, 589-600.
103. Chimge, N.-O.; Baniwal, S.K.; Little, G.H.; Chen, Y.; Kahn, M.; Tripathy, D.; Borok, Z.; Frenkel, B. Regulation of breast cancer metastasis by Runx2 and estrogen signaling: The role of SNAI2. Breast Cancer Res. 2011, 13, doi:10.1186/bcr3073.
104. Mendoza-Villanueva, D.; Zeef, L.; Shore, P. Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFb dependent expression of the Wnt antagonist, sclerostin. Breast Cancer Res. 2011, 13, doi:10.1186/bcr3048.
105. Katoh, Y.; Katoh, M. Hedgehog signaling, epithelial-to-mesenchymal transition and miRNA. Int. J. Mol. Med. 2008, 22, 271-275.
106. Weinberg, R.A. Leaving home early: Reexamination of the canonical models of tumor progression. Cancer Cell 2008, 14, 283-284.
107. Scheel, C.; Weinberg, R.A. Cancer stem cells and epithelial-mesenchymal transition: Concepts and molecular links. Semin. Cancer Biol. 2012, 22, 396-403.
108. Yang, J.; Weinberg, R.A. Epithelial-mesenchymal transition: At the crossroads of development and tumor metastasis. Dev. Cell 2008, 14, 818-829.
109. Foroni, C.; Broggini, M.; Generali, D.; Damia, G. Epithelial-mesenchymal transition and breast cancer: Role, molecular mechanisms and clinical impact. Cancer Treat. Rev. 2012, 38, 689-697.
110. Hennessy, B.T.; Gonzalez-Angulo, A.M.; Stemke-Hale, K.; Gilcrease, M.Z.; Krishnamurthy, S.; Lee, J.S.; Fridlyand, J.; Sahin, A.; Agarwal, R.; Joy, C.; et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 2009, 69, 4116-4124.
111. Howlett, A.R.; Bissell, M.J. The influence of tissue microenvironment (stroma and extracellular matrix) on the development and function of mammary epithelium. Epithel. Cell Biol. 1993, 2, 79-89.
112. Bonnomet, A.; Syne, L.; Brysse, A.; Feyereisen, E.; Thompson, E.W.; Noel, A.; Foidart, J.M.; Birembaut, P.; Polette, M.; Gilles, C. A dynamic in vivo model of epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of breast cancer. Oncogene 2012, 31, 3741-3753.
113. Creighton, C.J.; Chang, J.C.; Rosen, J.M. Epithelialmesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer. J. Mammary Gland Biol. Neoplasia 2010, 15, 253-260.
114. Jechlinger, M.; Grunert, S.; Beug, H. Mechanisms in epithelial plasticity and metastasis: Insights from 3D cultures and expression profiling. J. Mammary Gland Biol. Neoplasia 2002, 7, 415-432.
115. Hugo, H.; Ackland, M.L.; Blick, T. Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J. Cell. Physiol. 2007, 213, 374-383.
116. Chao, Y.L.; Shepard, C.R.; Wells, A. Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition. Mol. Cancer 2010, 9, doi:10.1186/1476-4598-9-179.
117. Patel, S.A.; Dave, M.A.; Murthy, R.G.; Helmy, K.Y.; Rameshwar, P. Metastatic breast cancer cells in the bone marrow microenvironment: Novel insights into oncoprotection. Oncol. Rev. 2011, 5, 93-102.
118. Kallergi, G.; Papadaki, M.A.; Politaki, E.; Mavroudis, D.; Georgoulias, V.; Agelaki, S. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Res. 2011, 13, doi:10.1186/bcr2896.
119. Lopes, N.; Paredes, J.; Costa, J.L.; Ylstra, B.; Schmitt, F. Vitamin D and the mammary gland: A review on its role in normal development and breast cancer. Breast Cancer Res. 2012, 14, doi:10.1186/bcr3178.
120. Lopes, N.; Carvalho, J.; Duraes, C.; Sousa, B.; Gomes, M.; Costa, J.L.; Oliveira, C.; Paredes, J.; Schmitt, F. 1Alpha,25-dihydroxyvitamin D3 induces de novo E-cadherin expression in triple-negative breast cancer cells by CDH1-promoter demethylation. Anticancer Res. 2012, 32, 249-257.
121. Chao, Y.; Wu, Q.; Acquafondata, M.; Dhir, R.; Wells, A. Partial mesenchymal to epithelial reverting transition in breast and prostate cancer metastases. Cancer Microenviron. 2012, 5, 19-28.
122. Korpal, M.; Lee, E.S.; Hu, G.; Kang, Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J. Biol. Chem. 2008, 283, 14910-14914.
123. Park, S.M.; Gaur, A.B.; Lengyel, E.; Peter, M.E. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008, 22, 894-907.
124. Wellner, U.; Schubert, J.; Burk, U.C.; Schmalhofer, O.; Zhu, F.; Sonntag, A.; Waldvogel, B.; Vannier, C.; Darling, D.; zur Hausen, A.; et al. The EMT activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat. Cell Biol. 2009, 11, 1487-1495.
125. Bracken, C.P.; Gregory, P.A.; Kolesnikoff, N.; Bert, A.G.; Wang, J.; Shannon, M.F.; Goodall, G.J. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res. 2008, 68, 7846-7854.
126. Mani, S.A.; Guo, W.; Liao, M.J.; Eaton, E.N.; Ayyanan, A.; Zhou, A.Y.; Brooks, M.; Reinhard, F.; Zhang, C.C.; Shipitsin, M.; et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133, 704-715.
127. Drasin, D.J.; Robin, T.P.; Ford, H.L. Breast cancer epithelial-to-mesenchymal transition: Examining the functional consequences of plasticity. Breast Cancer Res. 2011, 13, doi:10.1186/bcr3037.
128. Tomaskovic-Crook, E.; Thompson, E.W.; Thiery, J.P. Epithelial to mesenchymal transition and breast cancer. Breast Cancer Res. 2009, 11, doi:10.1186/bcr2416.
129. Sas, L.; Lardon, F.; Vermeulen, P.B.; Hauspy, J.; van Dam, P.; Pauwels, P.; Dirix, L.Y.; van Laere, S.J. The interaction between ER and NFκB in resistance to endocrine therapy. Breast Cancer Res. 2012, 14, doi:10.1186/bcr3196.
130. Pece, S.; Tosoni, D.; Confalonieri, S.; Mazzarol, G.; Vecchi, M.; Ronzoni, S.; Bernard, L.; Viale, G.; Pelicci, P.G.; di Fiore, P.P. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 2010, 140, 62-73.
131. Torsvik, A.; Bjerkvig, R. Mesenchymal stem cell signaling in cancer progression. Cancer Treat. Rev. 2013, 39, 180-188.
132. Palena, C.; Hamilton, D.H.; Fernando, R.I. Influence of IL-8 on the epithelial-mesenchymal transition and the tumor microenvironment. Future Oncol. 2012, 8, 713-722.
133. Buijs, J.T.; Petersen, M.; van der Horst, G.; van der Pluijm, G. Bone morphogenetic proteins and its receptors; therapeutic targets in cancer progression and bone metastasis? Curr. Pharm. Des. 2010, 16, 1291-1300.
134. Buijs, J.T.; Henriquez, N.V.; van Overveld, P.G.M.; van der Horst, G.; Que, I.; Schwaninger, R.; Rentsch, C.; ten Dijke, P.; Cleton-Jansen, A.-M.; Driouch, K.; et al. Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Res. 2007, 67, 8742-8751.
135. Fuxea, J.; Karlsson, M.C.I. TGF-β-induced epithelial-mesenchymal transition: A link between cancer and inflammation. Semin. Cancer Biol. 2012, 22, 455-461.
136. Zheng, Y.; Zhou, H.; Dunstan, C.R.; Sutherland, R.L.; Seibel, M.J. The role of the bone microenvironment in skeletal metastasis. J. Bone Oncol. 2013, 2, 47-57.
137. Chirgwin, J.M.; Mohammad, K.S.; Guise, T.A. Tumor-bone cellular interactions in skeletal metastases. J. Musculoskel. Neuron Interact. 2004, 4, 308-318.
138. Kozlow, W.; Guise, T.A. Breast cancer metastasis to bone: Mechanisms of osteolysis and implications for therapy. J. Mammary Gland Biol. Neoplasia 2005, 10, 169-180.
139. Kakonen, S.M.; Mundy, G.R. Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 2003, 97, 834-839.
140. Valcourt, U.; Kowanetz, M.; Niimi, H.; Heldin, C.-H.; Moustakas, A. TGF-β and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition. Mol. Biol. Cell 2005, 16, 1987-2002.
141. Kang, Y.; He, W.; Tulley, S.; Gupta, G.P.; Serganova, I.; Chen, C.R.; Manova-Todorova, K.; Blasberg, R.; Gerald, W.L.; Massagué, J. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc. Natl. Acad. Sci. USA 2005, 102, 13909-13914.
142. Kang, Y.; Siegel, P.M.; Shu, W.; Drobnjak, M.; Kakonen, S.M.; Cordón-Cardo, C.; Guise, T.A.; Massagué, J. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3, 537-549.
143. Sethi, N.; Kang, Y. Notch signaling: Mediator and therapeutic target of bone metastasis. BoneKey Rep. 2012, 1, doi:10.1038/bonekey.2012.2.